Clinical Trial Update: LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update of LYT-200 as a single agent and in combination with chemotherapy or tislelizumab in locally advanced or metastatic solid tumors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Head and Neck Cancer
• Pancreatic Cancer
• Urothelial Carcinoma

Drugs mentioned

• LYT-200 (LYT-200)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: PureTech | Conditions: Metastatic Cancer, Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED